- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
AZN
BUE
Week ended 07 Aug 2026
Weekly Investor Report
AstraZeneca PLC · Healthcare · Drug Manufacturers - General
Latest close
63,825 ARS
-4.1%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -9.5% below the Trend Line and sits at 48.2% of its 52-week range. The latest completed week returned -4.1%, after a -4.6% four-week move. The latest news-sentiment score is 67/100.
Setup score
41
out of 100
Latest Close
63,825 ARS
7 Aug 2026
1W Return
-4.1%
latest completed week
4W Return
-4.6%
short-term follow-through
12W Return
-5.2%
quarterly tape
Trend Breadth
75.0%
39 of 52 weeks active
Volume Ratio
4.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-4.1%
Latest completed week; four-week move -4.6%.
Indicator stack
41/33
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
67/100
21 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -9.5% below the Trend Line and sits at 48.2% of its 52-week range. The latest completed week returned -4.1%, after a -4.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 4.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4412-week average 0.53
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.44Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers
No recent accumulation markers. 3 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -4.6% over four weeks, -5.2% over 12 weeks, and 30.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year39
Trend breadth75.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.72Latest activity-pressure read.
Pressure change-51.1%Four-week change in activity pressure.
Leadership-17.27Latest relative-leadership reading.
RS change7.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment67/100
Weighted news tone is positive across 21 relevant articles.
15 positive · 6 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-20.0%Distance below the 52-week high.
13-week volatility6.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2616 weeks finished lower.
Best week+10.2%Week of 26 Jun.
Worst week-15.8%Week of 10 Jul.
Latest week-4.1%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains6
Flat weeks0
Modest losses11
Sharp losses5
Recent vol6.3%13-week weekly-return volatility.
Base vol5.2%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew4.2% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAR Healthcare
4-week rank20 / 20
Group average4.7%
Trend breadth60.0%
Trend60.0%active weekly trend signals
MD85.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
IndustryAR Drug Manufacturers - General
4-week rank13 / 13
Group average4.5%
Trend breadth76.9%
Trend76.9%active weekly trend signals
MD84.6%positive activity pressure
RS61.5%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape40/100
Trend, activity pressure, participation, and risk combine to a 40/100 tape read.
Indicator analysis11/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.44; 3 reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment67/100Weighted news tone is positive across 21 relevant articles.
U.K. regulator reaffirms safety of childhood vaccination Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 63,825 ARS | -4.1% | 70,525 ARS | 40,930 ARS | -0.72 | -17.27 | 13.1K | Off |
| 31 Jul 2026 | 66,556 ARS | -0.8% | 70,810 ARS | 40,522 ARS | -0.72 | -19.13 | 3.7K | Off |
| 24 Jul 2026 | 67,102 ARS | 1.6% | 70,942 ARS | 40,096 ARS | -0.51 | -18.41 | 604 | Off |
| 17 Jul 2026 | 66,059 ARS | -1.3% | 71,104 ARS | 39,668 ARS | -0.38 | -17.63 | 3.5K | Off |
| 10 Jul 2026 | 66,903 ARS | -15.8% | 71,268 ARS | 39,246 ARS | -0.47 | -18.67 | 2.1K | Off |
| 3 Jul 2026 | 79,499 ARS | 9.5% | 71,300 ARS | 38,818 ARS | -0.59 | -1.00 | 48 | Off |
| 26 Jun 2026 | 72,625 ARS | 10.2% | 70,921 ARS | 38,310 ARS | -0.88 | -7.13 | 1.2K | Off |
| 19 Jun 2026 | 65,900 ARS | -1.5% | 70,871 ARS | 37,846 ARS | -1.02 | -19.87 | 3 | Off |
| 12 Jun 2026 | 66,925 ARS | -4.6% | 70,976 ARS | 37,425 ARS | -0.97 | -20.06 | 343 | Off |
| 5 Jun 2026 | 70,125 ARS | 1.9% | 70,956 ARS | 36,997 ARS | -0.97 | -9.02 | 2.5K | Off |
| 29 May 2026 | 68,850 ARS | -1.4% | 70,701 ARS | 36,549 ARS | -1.01 | -12.81 | 2.9K | Off |
| 22 May 2026 | 69,825 ARS | 3.7% | 70,469 ARS | 36,109 ARS | -1.05 | -1.44 | 4.3K | Off |
| 15 May 2026 | 67,325 ARS | -0.6% | 70,316 ARS | 35,663 ARS | -1.09 | 0.44 | 549 | Off |
| 8 May 2026 | 67,750 ARS | -3.9% | 70,250 ARS | 35,232 ARS | -0.91 | -0.59 | 789 | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.